Catch up on all the latest news and developments from Cyprotex, your ADME-Tox specialist!
Don't miss a thing by signing up to receive our newsletters straight to your inbox.
News from Cyprotex
Holiday Greetings!
We celebrated our 25th anniversary this year, and we’re proud to reflect on how far we’ve come—and even more excited about the journey ahead!
This year has been a milestone for growth and innovation, highlighted by the addition of cutting-edge services, including our Diverse Modality offerings, Skin Sensitization Panel and updated Immunotoxicology Services.
We’d like to take this opportunity to thank you for being a part of this journey and wish you seasons greetings!
2024 Webinars
This year, Cyprotex hosted a series of insightful webinars delving into critical aspects of drug development and safety:
- Deciphering the Clinical DDI Between Atazanavir and Rosuvastatin
- Assessing Transporter DDI Risk During Drug Discovery and Development
- Drugging the Gut Microflora to Reduce Drug Toxicity
Explore these sessions to stay informed about the latest developments in the field and keep an eye on your inbox for more webinars in the new year.
ICH M12 Insights
This year, Cyprotex has provided in-depth analyses of the International Council for Harmonisation's (ICH) M12 guideline, a significant advancement in the evaluation of drug-drug interactions (DDIs). Our blog articles have explored the guidelines comprehensive recommendations for designing, conducting, and interpreting enzyme- or transporter-mediated DDI in vitro.
Read the blog series:
